Closed‐loop driven by control‐to‐range algorithm outperforms threshold‐low‐glucose‐suspend insulin delivery on glucose control albeit not on nocturnal hypoglycaemia in prepubertal patients with type 1 diabetes in a supervised hotel setting
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
This randomized control trial investigated glucose control with closed‐loop (CL) versus threshold‐low‐glucose‐suspend (TLGS) insulin pump delivery in pre‐pubertal children with type 1 diabetes in supervised hotel conditions. The patients [n = 24, age range: 7‐12, HbA1c: 7.5 ± 0.5% (58 ± 5 mmol/mol)] and their parents were admitted twice at a 3‐week interval. CL control to range or TLGS set at 3.9 mmoL/L were assessed for 48 hour in randomized order. Admissions included three meals and one snack, and physical exercise. Meal boluses followed individual insulin/carb ratios. While overnight (22:00‐08:00) per cent continuous glucose monitoring (CGM) time below 3.9 mmol/L (primary outcome) was similar, time in ranges 3.9 to 10.0 and 3.9 to 7.8 mmoL/L and mean CGM were all significantly improved with CL ( P < 0.001). These results were confirmed over the whole 48 hour. Disconnections between devices and limited accuracy of glucose sensors in the hypoglycaemic range appeared as limiting factors for optimal control. CL mode was well accepted while fear of hypoglycaemia was unchanged. CL did not minimize nocturnal hypoglycaemia exposure but improved time in target range compared to TLGS. Although safe and well‐accepted, CL systems would benefit from more integrated devices.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Miller, K. M., Foster, N. C., Beck, R. W., Bergenstal, R. M., DuBose, S. N., DiMeglio, L. A., Maahs, D. M., & Tamborlane, W. V. (2015) · Diabetes Care · doi:10.2337/dc15-0078 · Cited by 1,254
Threshold-based insulin-pump interruption for reduction of hypoglycemia
Bergenstal, R. M., Klonoff, D. C., Garg, S. K., Bode, B. W., Meredith, M., Slover, R. H., Ahmann, A. J., Welsh, J. B., Lee, S. W., & Kaufman, F. R. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1303576 · Cited by 652 · cited 1×
“Commercially available sensor-augmented pump therapy (SAP) with automated stopping of insulin infusion when continuous glucose monitoring (CGM) reaches a predefined glucose threshold [thresholdlow-glucose-suspend (TLGS)] has shown significant reduction of time in hypoglycaemia.(2,3) Investigational control-to-range (C…”
ResultLy, T. T., Nicholas, J. A., Retterath, A., Lim, E. M., Davis, E. A., & Jones, T. W. (2013) · JAMA · doi:10.1001/jama.2013.277818 · Cited by 411 · cited 1×
“Commercially available sensor-augmented pump therapy (SAP) with automated stopping of insulin infusion when continuous glucose monitoring (CGM) reaches a predefined glucose threshold [thresholdlow-glucose-suspend (TLGS)] has shown significant reduction of time in hypoglycaemia.(2,3) Investigational control-to-range (C…”
ResultMultinational Home Use of Closed-Loop Control Is Safe and Effective
Anderson, S. M., Raghinaru, D., Pinsker, J. E., Boscari, F., Renard, E., Buckingham, B. A., Nimri, R., Doyle, F. J., Brown, S. A., Keith-Hynes, P., et al. (2016) · Diabetes Care · doi:10.2337/dc15-2468 · Cited by 120
Self-citationDel Favero, S., Boscari, F., Messori, M., Rabbone, I., Bonfanti, R., Sabbion, A., Iafusco, D., Schiaffini, R., Visentin, R., Calore, R., et al. (2016) · Diabetes Care · doi:10.2337/dc15-2815 · Cited by 94
Troncone, A., Bonfanti, R., Iafusco, D., Rabbone, I., Sabbion, A., Schiaffini, R., Galderisi, A., Marigliano, M., Rapini, N., Rigamonti, A., et al. (2016) · Diabetes Care · doi:10.2337/dc16-1073 · Cited by 33
Cited by
Continuous glucose monitoring and metrics for clinical trials: an international consensus statement
Battelino, T., Alexander, C. M., Amiel, S. A., Arreaza-Rubin, G., Beck, R. W., Bergenstal, R. M., Buckingham, B. A., Carroll, J., Ceriello, A., Chow, E., et al. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00319-9 · Cited by 831
Bekiari, E., Kitsios, K., Thabit, H., Tauschmann, M., Athanasiadou, E., Karagiannis, T., Haidich, A.-B., Hovorka, R., & Tsapas, A. (2018) · BMJ · doi:10.1136/bmj.k1310 · Cited by 437
7. Diabetes Technology: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s007 · Cited by 358
7. Diabetes Technology: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Echouffo-Tcheugui, J. B., Ekhlaspour, L., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s007 · Cited by 348
7. Diabetes Technology: Standards of Care in Diabetes — 2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Hilliard, M. E., Isaacs, D., Johnson, E. L., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s007 · Cited by 301
Grunberger, G., Sherr, J., Allende, M., Blevins, T., Bode, B., Handelsman, Y., Hellman, R., Lajara, R., Roberts, V. L., Rodbard, D., et al. (2021) · Endocrine Practice · doi:10.1016/j.eprac.2021.04.008 · Cited by 288
7. Diabetes Technology: Standards of Care in Diabetes—2024
American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Ekhlaspour, L., Hilliard, M. E., Johnson, E. L., Khunti, K., et al. (2024) · Diabetes Care · doi:10.2337/dc24-s007 · Cited by 281
7. Diabetes Technology: Standards of Medical Care in Diabetes—2021
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s007 · Cited by 202
Metadata
- Authors
- Renard, E., Tubiana‐Rufi, N., Bonnemaison‐Gilbert, E., Coutant, R., Dalla‐Vale, F., Farret, A., Poidvin, A., Bouhours‐Nouet, N., Abettan, C., Storey‐London, C., Donzeau, A., Place, J., & Breton, M. D.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2018-08-21
- Volume
- 21
- Issue
- 1
- Pages
- 183-187
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2883497907
- Cited by
- 31
- References
- 6
- FWCI
- 2.90
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.